PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20965162-5 2011 Additionally, rosiglitazone increased circulating adiponectin, which was negatively correlated with serum TNF-alpha. Rosiglitazone 14-27 tumor necrosis factor Rattus norvegicus 106-115 22219595-13 2011 Additionally, rosiglitazone significantly reduced the concentration of TNF-alpha, IL-1beta, IL-6 and ALT in sham-operated rats, but not in BDL rats, in response to LPS (3 mg/kg). Rosiglitazone 14-27 tumor necrosis factor Rattus norvegicus 71-80 23125852-0 2012 Influence of Rosiglitazone on the Expression of PPARgamma, NF-kappaB, and TNF-alpha in Rat Model of Ulcerative Colitis. Rosiglitazone 13-26 tumor necrosis factor Rattus norvegicus 74-83 23125852-8 2012 Furthermore, in the rosiglitazone treatment group, DAI and CMDI decreased significantly on the 14-day, 21-day, and 35-day timepoints compared to the UC model group; the colonic expression of NF-kappaB and TNF-alpha decreased compared to UC model group at all timepoints, but the PPARgamma expression increased significantly. Rosiglitazone 20-33 tumor necrosis factor Rattus norvegicus 205-214 23125852-10 2012 Rosiglitazone can alleviate colonic mucosal inflammation and have the protective role on UC by upregulating PPARgamma expression and downregulating NF-kappaB and TNF-alpha expression. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 162-171 20382448-5 2012 Magnetic resonance (MR) imaging revealed an age-related increase in T1 relaxation time and, importantly, treatment of aged rats with rosiglitazone reversed the age-related increases in astrogliosis and astrocytosis, TNF-alpha concentration and T1 relaxation time. Rosiglitazone 133-146 tumor necrosis factor Rattus norvegicus 216-225 21959602-9 2011 Treatment with rosiglitazone improved survival rate, decreased the markers of organ injury, and suppressed the release of TNF-alpha, IL-6, and MCP-1 after HS in rats. Rosiglitazone 15-28 tumor necrosis factor Rattus norvegicus 122-131 21959602-10 2011 CONCLUSIONS: Treatment with rosiglitazone suppresses the release of serum TNF-alpha, IL-6 and MCP-1, and ameliorates HS-induced organ damage in rats. Rosiglitazone 28-41 tumor necrosis factor Rattus norvegicus 74-83 21893696-11 2011 The activated PPAR-gamma inhibit the expression of proinflammatory factors, such as IL-6, TNF-alpha, and neutrophil chemotaxis, which was evidenced by MPO reduction in serum and colon homogenates mediated by rosiglitazone. Rosiglitazone 208-221 tumor necrosis factor Rattus norvegicus 90-99 20965162-6 2011 These results indicated that rosiglitazone improved NASH by directly modulating adiponectin receptor 1 and adiponectin receptor 2 in various adipose tissues, or indirectly possibly via decreasing serum TNF-alpha. Rosiglitazone 29-42 tumor necrosis factor Rattus norvegicus 202-211 18455351-5 2008 We found that rosiglitazone inhibited the expression of CD40, tumor necrosis factor (TNF-alpha), and microglial activation in different regions of hippocampus. Rosiglitazone 14-27 tumor necrosis factor Rattus norvegicus 85-94 21224499-14 2010 Rosiglitazone decreased the expression of inflammatory cytokines, such as IL-6 and TNF-alpha, both in serum and in intestinal homogenates. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 83-92 21224499-16 2010 Rosiglitazone reduces inflammation by decreasing the expression of IL-6 and TNF-alpha. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 76-85 19356226-8 2009 RESULTS: Our data shows involvement of TNF-alpha in preventing cisplatin induced nephrotoxicity by rosiglitazone. Rosiglitazone 99-112 tumor necrosis factor Rattus norvegicus 39-48 19237016-10 2009 RESULTS: Prophylactic administration of rosiglitazone attenuated (1) serum amylase level; (2) myeloperoxidase activity of pancreatic and pulmonary tissue; (3) expression of tumor necrosis factor-alpha and ICAM-1 in pancreas and lung; (4) pancreas and lung pathological damage. Rosiglitazone 40-53 tumor necrosis factor Rattus norvegicus 173-200 20034949-9 2011 Rosiglitazone diminished the increase in HR, decreased the markers of organ injury (GOT, GPT, BUN, Cre, LDH, CPK, glucose) and inflammatory biomarkers (TNF-alpha, IL-6), and did not affect MAP after LPS. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 152-161 20034949-10 2011 In conclusion, rosiglitazone ameliorated endotoxin shock-induced markers of organ injury and suppressed the release of TNF-alpha and IL-6 in conscious rats. Rosiglitazone 15-28 tumor necrosis factor Rattus norvegicus 119-128 27990201-1 2009 BACKGROUND: Rosiglitazone, an insulin sensitizing agent, has been recently implicated in the control of inflammatory processes and modulation of expression of various cytokines such as tumor necrosis factor (TNF-alpha). Rosiglitazone 12-25 tumor necrosis factor Rattus norvegicus 208-217 19527823-5 2009 RESULTS: The levels of FBG, FINS, TG, TNF-alpha and 2-h PG all decreased significantly in the rosiglitazone and neferine groups compared with the insulin resistance (IR) model group. Rosiglitazone 94-107 tumor necrosis factor Rattus norvegicus 38-47 16796890-17 2006 (3) The serum TNF-alpha levels of the rosiglitazone and metformin treatment groups were 124.6 pg/mL +/- 21.0 pg/mL, 154.9 pg/mL +/- 32.5 pg/mL respectively, both significantly lower than that of the NAFLD group (324.2 pg/mL +/- 34.2 pg/mL, P < 0.001 and P < 0.05). Rosiglitazone 38-51 tumor necrosis factor Rattus norvegicus 14-23 18479673-13 2008 RSG, however, significantly attenuated MPO activity and qualitatively decreased IL-1beta and TNF-alpha expression compared to vehicle-treated group. Rosiglitazone 0-3 tumor necrosis factor Rattus norvegicus 93-102 17594812-11 2007 CONCLUSIONS: PPAR-gamma specific agonist rosiglitazone can play an anti-inflammatory role by IKK-beta/I kappa B/NF-kappa B/TNF alpha signal ways, and minimize inflammatory reaction at cellular and molecular levels. Rosiglitazone 41-54 tumor necrosis factor Rattus norvegicus 123-132 16770837-8 2007 ADMA (30 microM) significantly increased the activity of NF-kappaB and elevated the levels of ICAM-1 and TNF-alpha, and pre-treatment with rosiglitazone (10 or 30 microM) markedly inhibited the increased activity of NF-kappaB and reduced the elevated levels of TNF-alpha and ICAM-1 induced by ADMA in cultured endothelial cells. Rosiglitazone 139-152 tumor necrosis factor Rattus norvegicus 105-114 16770837-8 2007 ADMA (30 microM) significantly increased the activity of NF-kappaB and elevated the levels of ICAM-1 and TNF-alpha, and pre-treatment with rosiglitazone (10 or 30 microM) markedly inhibited the increased activity of NF-kappaB and reduced the elevated levels of TNF-alpha and ICAM-1 induced by ADMA in cultured endothelial cells. Rosiglitazone 139-152 tumor necrosis factor Rattus norvegicus 261-270 16796890-18 2006 The liver TNF-alpha levels of the rosiglitazone and metformin treatment groups were 0.24 +/- 0.14 and 0.30 +/- 0.12 respectively, both significantly lower than that of the NAFLD group (0.85 +/- 0.12, both P < 0.001). Rosiglitazone 34-47 tumor necrosis factor Rattus norvegicus 10-19 15876425-7 2005 Administration of rosiglitazone corrected the disorders in morphology associated to lesions, significantly reduced the ulceration index, the rise of myeloperoxidase (MPO) and the levels of tumour necrosis factor alpha (TNF-alpha). Rosiglitazone 18-31 tumor necrosis factor Rattus norvegicus 219-228 16307220-9 2005 RESULTS: Rosiglitazone pretreatment significantly attenuated the increases in W/D ratio, MPO activity and MDA levels, and reduced pulmonary overproduction of TNF-alpha and CINC-1 as well as expression of ICAM-1 following endotoxemia. Rosiglitazone 9-22 tumor necrosis factor Rattus norvegicus 158-167 16157299-7 2005 The expression of visfatin and adiponectin mRNA in visceral fat deposits was elevated by rosiglitazone or fenofibrate treatments when compared to untreated OLETF rats (P<0.05), whereas, TNF-alpha mRNA was down-regulated by these drugs (P<0.05). Rosiglitazone 89-102 tumor necrosis factor Rattus norvegicus 189-198 16157299-8 2005 These results suggest that rosiglitazone and fenofibrate may prevent type 2 diabetes by regulating adipocytokines including visfatin, adiponectin, and TNF-alpha. Rosiglitazone 27-40 tumor necrosis factor Rattus norvegicus 151-160 15365619-0 2004 Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-alpha induction of p38 and p42/p44 mitogen-activated protein kinases. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 93-102 15665514-9 2005 Treatment of neonatal rat ventricular myocytes with 10 micromol/L rosiglitazone enhanced TNF-alpha- and lipopolysaccharide-induced NF-kappaB-dependent transcription by approximately 1.8- and approximately 1.4-fold respectively, and TNF-alpha-induced IL-6 secretion by n1.5-fold. Rosiglitazone 66-79 tumor necrosis factor Rattus norvegicus 89-98 15665514-9 2005 Treatment of neonatal rat ventricular myocytes with 10 micromol/L rosiglitazone enhanced TNF-alpha- and lipopolysaccharide-induced NF-kappaB-dependent transcription by approximately 1.8- and approximately 1.4-fold respectively, and TNF-alpha-induced IL-6 secretion by n1.5-fold. Rosiglitazone 66-79 tumor necrosis factor Rattus norvegicus 232-241 15665514-0 2005 The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. Rosiglitazone 23-36 tumor necrosis factor Rattus norvegicus 69-78 15665514-0 2005 The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. Rosiglitazone 23-36 tumor necrosis factor Rattus norvegicus 134-143 15365619-11 2004 Rosiglitazone ameliorated insulin resistance by TNF-alpha in brown adipocytes, restoring completely insulin-stimulated glucose uptake and insulin-induced GLUT4 translocation to plasma membrane in parallel to the insulin signalling cascade IRS-2/PI 3-kinase/Akt. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 48-57 15365619-12 2004 CONCLUSIONS/INTERPRETATION: Rosiglitazone treatment impaired TNF-alpha activation of p38 and p42/p44MAPK, restoring insulin signalling and leading to normalisation of glucose uptake. Rosiglitazone 28-41 tumor necrosis factor Rattus norvegicus 61-70 9931102-14 1999 We therefore investigated the effects of the thiazolidinediones troglitazone (TRO) and rosiglitazone (RSG) on TNF-alpha-induced migration. Rosiglitazone 87-100 tumor necrosis factor Rattus norvegicus 110-119 9931102-14 1999 We therefore investigated the effects of the thiazolidinediones troglitazone (TRO) and rosiglitazone (RSG) on TNF-alpha-induced migration. Rosiglitazone 102-105 tumor necrosis factor Rattus norvegicus 110-119 33339154-9 2020 The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516. Rosiglitazone 57-70 tumor necrosis factor Rattus norvegicus 166-174 32606592-6 2020 RGTZ treatment also inhibited TGF-beta and NF-kappaB pathway activation, decreased expression of fibronectin, collagen I, alpha-SMA, vimentin, MCP-1, RANTES, TNF-alpha, and IL-1beta, and increased E-cadherin expression in the kidneys of HN rats. Rosiglitazone 0-4 tumor necrosis factor Rattus norvegicus 158-167 32876675-0 2020 Rosiglitazone ameliorates radiation-induced intestinal inflammation in rats by inhibiting NLRP3 inflammasome and TNF-alpha production. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 113-122 32876675-6 2020 We found that rosiglitazone ameliorated radiation-induced intestinal injury in rats by suppressing the expression of caspase-1, NLRP3, IL-1beta and TNF-alpha. Rosiglitazone 14-27 tumor necrosis factor Rattus norvegicus 148-157 32876675-7 2020 Treatment with rosiglitazone in vitro reduced the expression of NLRP3, and the NLRP3 activator monosodium urate (MSU) reversed the inhibition of IL-1beta and TNF-alpha by rosiglitazone in macrophages. Rosiglitazone 15-28 tumor necrosis factor Rattus norvegicus 158-167 32876675-7 2020 Treatment with rosiglitazone in vitro reduced the expression of NLRP3, and the NLRP3 activator monosodium urate (MSU) reversed the inhibition of IL-1beta and TNF-alpha by rosiglitazone in macrophages. Rosiglitazone 171-184 tumor necrosis factor Rattus norvegicus 158-167 32876675-8 2020 MSU reversed the protective effect of rosiglitazone on radiation-induced intestinal injury in rats by reversing the rosiglitazone-induced inhibition of IL-1beta and TNF-alpha. Rosiglitazone 38-51 tumor necrosis factor Rattus norvegicus 165-174 32876675-8 2020 MSU reversed the protective effect of rosiglitazone on radiation-induced intestinal injury in rats by reversing the rosiglitazone-induced inhibition of IL-1beta and TNF-alpha. Rosiglitazone 116-129 tumor necrosis factor Rattus norvegicus 165-174 30682409-10 2019 Furthermore, rosiglitazone treatment inhibited TGF-beta and NF-kappaB pathway activation, decreased collagen I, collagen IV, alpha-SMA, MCP-1, ICAM-1, TNF-alpha, and IL-1beta expression, and increased E-cadherin expression in renal allograft tissues from the CRAD rats. Rosiglitazone 13-26 tumor necrosis factor Rattus norvegicus 151-160 31957860-10 2020 The protein level of TNF-alpha in serum, the mRNA expression level of TNF-alpha in myocardial tissues, and the activity of NF-kappaB in group C treated with rosiglitazone were lower than those in group A (p<0.05). Rosiglitazone 157-170 tumor necrosis factor Rattus norvegicus 21-30 31957860-10 2020 The protein level of TNF-alpha in serum, the mRNA expression level of TNF-alpha in myocardial tissues, and the activity of NF-kappaB in group C treated with rosiglitazone were lower than those in group A (p<0.05). Rosiglitazone 157-170 tumor necrosis factor Rattus norvegicus 70-79 31957860-11 2020 CONCLUSIONS: Rosiglitazone can alleviate myocardial injury in septic rats by suppressing the TNF-alpha expression and this process is associated with the regulation on the NF-kappaB signal transduction pathway. Rosiglitazone 13-26 tumor necrosis factor Rattus norvegicus 93-102 31493866-6 2019 The in vitro experiments showed that rosiglitazone treatment repressed the expression of TNFalpha and IL-6 induced by antigen-challenged RBL-2H3 cells in a peroxisome proliferator-activated receptor gamma (PPARgamma)-independent manner, which was related to the repression of protein kinase C (PKC)-beta1 activation. Rosiglitazone 37-50 tumor necrosis factor Rattus norvegicus 89-97 28291540-11 2017 Rosiglitazone attenuated the free fatty acids-induced increase in reactive oxygen species, TNF-alpha, NOX2, and NF-kappaB; blocking AMPK-alpha by siRNA abolished the effects of rosiglitazone. Rosiglitazone 0-13 tumor necrosis factor Rattus norvegicus 91-100 29730170-10 2018 Besides, rosiglitazone administration significantly decreased the levels of TNF-alpha, IL-1beta, SOD and MDA in hippocampus. Rosiglitazone 9-22 tumor necrosis factor Rattus norvegicus 76-85 26394869-7 2016 Western blot analysis showed that rosiglitazone significantly decreased protein expression levels of COX-2 and production of pro-inflammatory markers, including TNF-alpha and IL-6, in D-GaIN/LPS-treated rat liver. Rosiglitazone 34-47 tumor necrosis factor Rattus norvegicus 161-170 26947332-4 2016 Compared with the vehicle-treated group, rosiglitazone treatment suppressed production of TNFalpha at 24 h after TBI, attenuated activation of microglia/macrophages and increased survival of CA3 neurons but had no effect on lesion volume at 21 d after TBI. Rosiglitazone 41-54 tumor necrosis factor Rattus norvegicus 90-98 23569141-6 2013 RESULTS: At 24 h after SCI, apoptosis and TNFalpha, IL-1beta and MPO concentrations were significantly lower in the rosiglitazone group than in the vehicle and SCI groups. Rosiglitazone 116-129 tumor necrosis factor Rattus norvegicus 42-50 26178497-0 2015 [Effects of rosiglitazone on levels of TNFalpha in septic rats with acute kidney injury]. Rosiglitazone 12-25 tumor necrosis factor Rattus norvegicus 39-47 26178497-1 2015 OBJECTIVE: To investigate the influence of rosiglitazone on tumor necrosis factor-alpha (TNFalpha) of rats in sepsis with acute kidney injury. Rosiglitazone 43-56 tumor necrosis factor Rattus norvegicus 60-87 26178497-1 2015 OBJECTIVE: To investigate the influence of rosiglitazone on tumor necrosis factor-alpha (TNFalpha) of rats in sepsis with acute kidney injury. Rosiglitazone 43-56 tumor necrosis factor Rattus norvegicus 89-97 26178497-15 2015 CONCLUSION: Rosiglitazone can inhibit the expression of TNFalpha in serum of septic rats, reduce the inflammatory reaction, reduce kidney injury, improve the renal function. Rosiglitazone 12-25 tumor necrosis factor Rattus norvegicus 56-64 24839089-5 2014 The results showed that rosiglitazone attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner. Rosiglitazone 24-37 tumor necrosis factor Rattus norvegicus 150-177 24839089-5 2014 The results showed that rosiglitazone attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner. Rosiglitazone 24-37 tumor necrosis factor Rattus norvegicus 179-188 24001946-5 2013 Pretreatment of rosiglitazone prevents cisplatin induced nephrotoxicity which was, clearly evident from the renal biochemical parameters like reduced BUN, creatinine and TNFalpha levels, and increased albumin levels, which was also supported by histopathological studies of the kidneys. Rosiglitazone 16-29 tumor necrosis factor Rattus norvegicus 170-178 23783408-11 2013 The rosiglitazone group had significantly decreased levels of the inflammatory cytokine, tumor necrosis factor (TNF)-alpha (P<0.01). Rosiglitazone 4-17 tumor necrosis factor Rattus norvegicus 89-122 25399210-7 2014 RESULTS: Rosiglitazone treatment increased creatinine clearance and plasma transferrin, and decreased urinary ACR, HbA1c, plasma TNF-alpha, ICAM-1, and serum lipid peroxide levels without affecting the altered lipid profile. Rosiglitazone 9-22 tumor necrosis factor Rattus norvegicus 129-138 22842585-8 2012 In addition, rosiglitazone attenuated in production of both COX-2 and TNF-alpha expression. Rosiglitazone 13-26 tumor necrosis factor Rattus norvegicus 70-79